SEL 212

Drug Profile

SEL 212

Alternative Names: Non-immunogenic uricase; Pegadricase-SVP; Pegsiticase-SVP; SEL-037/SEL-110; SEL-212; SVP-Rapamycin/pegsiticase

Latest Information Update: 10 Apr 2017

Price : $50

At a glance

  • Originator Selecta Biosciences
  • Class Antigouts; Enzymes; Oxidoreductases; Polyethylene glycols; Recombinant proteins; Synthetic vaccines
  • Mechanism of Action Urate oxidase stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Gout

Most Recent Events

  • 27 Mar 2017 Efficacy and adverse event data from a phase II trial in Gout released by Selecta Biosciences
  • 27 Mar 2017 Selecta plans a phase III trial for Gout in USA in 2018
  • 07 Dec 2016 Efficacy and Adverse events data from a phase Ia and phase Ib trials in Hyperuricaemia released by Selecta Biosciences
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top